Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 728 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Working to Make Cancer Clinical Trials More Inclusive: A Q&A With... October 6, 2022 EMA Recommends Granting a Marketing Authorisation for Tarlatamab April 17, 2026 Restaurant Opens Early For A 3-Year-Old Girl With Leukemia So She... February 21, 2020 Sugar and cancer – what you need to know October 20, 2020 Load more HOT NEWS Efficacy and Safety of Adjuvant Pertuzumab, Trastuzumab and Chemotherapy After 6... Doctors Want Breast Cancer Warning Label Put On Cheese Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,...
